Skip to search formSkip to main contentSkip to account menu

CPI 613

Known as: Alpha-Lipoic Acid Analogue CPI-613, CPI-613, CPI613 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

CaprylatesSulfides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and…
Background: Acute myeloid leukemia is an aggressive malignancy with poor outcomes especially in patients 60 years of age or… 
2016
2016
TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)
Background: CPI-613 is a first in class agent that inhibits pyruvate dehydrogenase (PDH) and a-ketogluterate dehydrogenase. We… 
2015
2015
Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML).
7015 Background: CPI-613 is a novel agent that targets mitochondrial metabolism. It inhibits mitochondrial respiration in AML… 
2014
2014
Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti…
STUDY RATIONALE AND OBJECTIVES Via genetic alterations, malignant transformation and proliferation are associated with extensive… 
2013
2013
A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies
Background Altered metabolism is a hallmark of cancer, including hematologic malignancies. Cancer cells alter the normally… 
2012
2012
Translational assessment of the efficacy of CPI-613 against pancreatic cancer in animal models versus patients with stage IV disease.
3075 Background: CPI-613 is a novel agent that selectively targets the altered mitochondrial enzymes of tumor cells, causing… 
2012
2012
CPI-613, AN INVESTIGATIONAL NOVEL ANTI-CANCER AGENT, PROVIDES LONG-TERM STABLE DISEASE WITHOUT SIGNIFICANT ADVERSE EFFECTS IN A PATIENT WITH STAGE IV RELAPSED HEPATOCELLULAR CARCINOMA
The current case study describes the safety and prolonged therapeutic effect of an investigational drug (CPI-613) in a patient… 
2012
2012
Evaluation of the first-in-class antimitochondrial metabolism agent CPI-613 in hematologic malignancies.
6524^ Background: Altered metabolism is a hallmark of cancer, including hematologic malignancies. Most tumor cells use glycolysis… 
2011
2011
Long-Term Stable Disease of Stage IV Pancreatic Neuroendocrine Tumors and Without Significant Adverse Effect by CPI-613, an Investigational Novel Anti-Cancer Agent
Introduction: The current case study describes the safety and prolonged therapeutic effect of an investigational drug (CPI-613… 
2010
2010
Uncommon Toxicologic Profile at Toxic Doses of CPI-613 (an Agent Selectively Alters Tumor Energy Metabolism) in Rats and Minipigs Reflects Novel Mechanism
Problem statement: CPI-613 is a novel anticancer agent and the toxicological profile has not been assessed. Accordingly, the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)